Mini-Monovision Outcomes Compared To Emmetropia Target With An Extended Depth Of Focus Iol

Published 2023 - 41st Congress of the ESCRS

Reference: FP32.05 | Type: Free paper | DOI: 10.82333/mnk5-n562

Authors: James Kirkpatrick* ¹

¹Newmedica,Gloucester,United Kingdom

Purpose

To compare visual acuity, visual disturbances, patient satisfaction and spectacle independence in subjects with mini-monovision and emmetropia target implanted bilaterally with AcrySof IQ Vivity IOL.

Setting

Multicenter, ambispective registry study conducted in Europe, Australia and New Zealand evaluating the performance of subjects bilaterally implanted with AcrySof IQ Vivity and/or AcrySof IQ Vivity Toric IOL in a real world setting through routine clinical practice.

Methods

Binocular uncorrected and distance corrected visual acuities at distance, intermediate (66 cm) and near (40 cm) were evaluated at the study entry visit at 3-6 months post-implantation (UCDVA/BCDVA, UCIVA/DCIVA and UCNVA/DCNVA). Subject satisfaction and spectacle independence were recorded via validated questionnaires, using Catquest 9-SF and IOLSAT, respectively. Patient reports of visual disturbances were also assessed. Mini-monovision group was defined through MRSE at study entry visit when at least one eye with MRSE less than or equal to -0.50 D and the absolute difference in MRSE between two eyes were greater than or equal to 0.50 D. Emmetropia group were all the other subjects.

Results

The mini-monovision group involved 202 subjects versus 649 subjects in the emmetropia group. Binocular mean logMAR (SD) UCDVA, UCIVA and UCNVA were 0.027 (0.100), 0.071 (0.114) and 0.203 (0.141) for the mini-monovision group and 0.005 (0.101), 0.089 (0.123) and 0.258 (0.154) for the emmetropia group, respectively. Patients reported never/rarely using spectacles at near, intermediate and distance by 75.2%, 92.6% and 90.0% for the mini-monovision and 56.5%, 88.4% and 94.1% for the emmetropia group, respectively. More than 90% of subjects reported no halos, glare and starbursts in both groups, and 89.9% and 91.6% were satisfied with their sight for the mini-monovision and emmetropia groups, respectively.

Conclusions

Targeting mini-monovision with AcrySof IQ Vivity IOL may improve uncorrected visual acuity at near and intermediate distance, as well as spectacle independence compared to emmetropia target while maintaining performance at distance with a low level of visual disturbances.